Browse and enrol in our EQA schemes

Explore our range of EQA schemes to support laboratory quality, accreditation, and compliance with international standards. Filter by category to find the right scheme for your testing services. Prefer a PDF?

Download the 2027 catalogue

Showing 1 - 16 of 84 results

No Schemes Found

We couldn't find any schemes that match your search criteria. Please try again with different filters.

Assessment of FLT3-ITD, FLT3-TKD, IDH1 and NPM1 variant detection and clinical interpretation in AML testing.

Haemato-Oncology

09-AML-27

DNA in TE Buffer NGS, PCR based +1NGS, PCR based, Sanger sequencing
Register

Closes 1 Mar 2027

Survey

To be finalised

Results


To be finalised

Methylation and copy number analysis for BWS and SRS testing.

Not available in China and Hong Kong in 2027 due to import restrictions

Genomic and Inherited Disorders

01-BWS-27

DNA in TE Buffer Methylation, MLPA
Register

Closes 30 Nov 2026

Survey

January - March 2027

Results

 August 2027

Sponsored!

PIK3CA, AKT1 and PTEN gene testing in breast cancer (FFPE)

Molecular Pathology

02-BRCA-AKT-27

FFPE CNV, NGS +2CNV, NGS, Panel testing, PCR based
Register

Closes 28 Feb 2027

Survey

June - August 2027

Results

December 2027 - January 2028

Sponsored!

ESR1 and PIK3CA testing in cfDNA (plasma) for metastatic breast cancer. This EQA is sponsored.

Molecular Pathology

02-BRCA-ESR1-27

Plasma cfDNA NGS, Panel testing +1NGS, Panel testing, PCR based
Register

Closes 28 Feb 2027

Survey

September - November 2027

Results

May - June 2028

Panel testing for Cardiac disorders (targeted NGS/ virtual panel /clinical exome / WES / WGS). This EQA has options for Arrythmia panel, Cardiomyopathy panel, and all Cardiac Disorders.

Genomic and Inherited Disorders

01-CARD-27

DNA in TE Buffer CNV, MLPA +6CNV, MLPA, NGS, Panel testing, PCR based, Sanger sequencing, Whole exome sequencing, Whole genome sequencing
Register

Closes 30 Nov 2026

Survey

January - March 2027

Results

 August 2027

EQA for quality and quantity of cfDNA extracted from plasma. There are two rounds of EQA per year which need to be purchased separately. This EQA will be distributed in March 2027. This EQA is sponsored.

Pre-analytical processes

06-CFDNA-RD1-27

Plasma cfDNA DNA extraction
Register

Closes 30 Dec 2026

Survey

March - April 2027

Results

Aug-27

EQA for quality and quantity of cfDNA extracted from plasma. There are two rounds of EQA per year which need to be purchased separately. This EQA will be distributed in Sept 2027. This EQA is sponsored.

Pre-analytical processes

06-CFDNA-RD2-27

Plasma cfDNA DNA extraction
Register

Closes 28 Feb 2027

Survey

September - October 2027

Results

 February 2028

PMP22 deletion/duplication testing for CMT/HNPP, this EQA has options for PMP22 targeted testing and panel testing for CMT/HNPP associated genes (Germline DNA).

CMT targeted option: Not available in China and Hong Kong in 2027 due to import restrictions.

Genomic and Inherited Disorders

01-CMT-27

DNA in TE Buffer CNV, MLPA +5CNV, MLPA, NGS, Panel testing, Sanger sequencing, Whole exome sequencing, Whole genome sequencing
Register

Closes 30 Nov 2026

Survey

January - March 2027

Results

  August 2027

KRAS, NRAS, BRAF and PIK3CA gene testing in colorectal cancer (FFPE).

Molecular Pathology

02-CRC-27

FFPE NGS, Panel testing +1NGS, Panel testing, PCR based
Register

Closes 28 Feb 2027

Survey

June - August 2027

Results

 December 2027 - January 2028

Sponsored!

Identification of different types of variants and genomic signatures by CGP in solid tumour (FFPE). This is a genotyping EQA only.

Molecular Pathology

02-CGP-27

FFPE CNV, NGS +4CNV, NGS, Panel testing, Whole exome sequencing, Whole genome analysis CNV, Whole genome sequencing
Register

Closes 1 Mar 2027

Survey

June - August 2027.

Results

December 2027 -  January 2028

CYP21A2 testing for Congenital Adrenal Hyperplasia (CAH) (germline DNA testing)

Genomic and Inherited Disorders

01-CAH-27

DNA in TE Buffer CNV, MLPA +3CNV, MLPA, NGS, PCR based, Sanger sequencing
Register

Closes 30 Nov 2026

Survey

January - March 2027

Results

 August 2027

Point-of-care molecular testing (POCT) of CYP2C19 for optimisation of antiplatelet therapy (Artificial Buccal swabs)

Point of Care Testing (POCT)

07-POCT-CYP2C19-27

Artificial Buccal Swab PCR based
Register

Closes 22 Oct 2027

Survey

4 weeks after sample dispatch

Results

N/A

CFTR testing for Cystic Fibrosis (germline DNA testing). To participate in EQA for Cystic Fibrosis, please go to our partner organisation’s (CF Network) website (https://eqascheme.org)

Genomic and Inherited Disorders

01-CF-27

DNA in TE Buffer PCR based
Survey

N/A

Results

N/A

One set of 8 patient-like swab-based materials designed to help implement and verify POCT devices for CYP2C19 testing. See https://www.emqn.org/our-eqa-schemes/poct/ for more information.

Point of Care Testing (POCT)

07-DVS-CYP2C19X01-27

Artificial Buccal Swab Not applicable

Closing soon

Register

Closes today

Survey

Not applicable

Results

Not applicable

Two sets of 8 patient-like swab-based materials designed to help implement and verify POCT devices for CYP2C19 testing. See https://www.emqn.org/our-eqa-schemes/poct/ for more information.

Point of Care Testing (POCT)

07-DVS-CYP2C19X02-27

Artificial Buccal Swab Not applicable

Closing soon

Register

Closes today

Survey

Not applicable

Results

Not applicable

Three sets of 8 patient-like swab-based materials designed to help implement and verify POCT devices for CYP2C19 testing. See https://www.emqn.org/our-eqa-schemes/poct/ for more information.

Point of Care Testing (POCT)

07-DVS-CYP2C19X03-27

Artificial Buccal Swab Not applicable

Closing soon

Register

Closes today

Survey

Not applicable

Results

Not applicable

Register Interest

Express your interest in ''.

Watch on YouTube (opens in a new tab)